2019
DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome
Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome. Clinical Genitourinary Cancer 2019, 17: 299-305.e1. PMID: 31204211, DOI: 10.1016/j.clgc.2019.05.004.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaDisease-free survivalAdvanced clear cell renal cell carcinomaDDR pathway alterationPathway alterationsLocalized Clear Cell Renal Cell CarcinomaDecreased disease-free survivalTCGA databaseShorter disease-free survivalCopy number alterationsTherapeutic agentsCox regression analysisT3-4 diseaseClear-Cell RenalRenal cell carcinomaDDR pathwaysPresence of mutationsT3a diseaseNeoadjuvant therapyOverall survivalPoor outcomeCell carcinomaCommon subtypeDisease progressionKidney cancer
2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh riskThe Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M
Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Song H, Choe S, Kim D, Kim S, Ha Y, Moon S, Lee G, Kim I, Yun S, Kim W. The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M. The American Journal Of Chinese Medicine 2018, 46: 689-705. PMID: 29595070, DOI: 10.1142/s0192415x18500362.Peer-Reviewed Original ResearchConceptsCentromere protein MBladder cancerBC patientsGarlic extractBetter progression-free survivalNude mouse xenograft modelProgression-free survivalCisplatin-treated miceBALB/cTissue microarray analysisNegative control miceMouse xenograft modelBC cell linesEffect of garlicMicroarray analysisCisplatin groupControl miceTumor weightControl tumorsTumor volumeNormal controlsXenograft modelSide effectsBody weightTumor tissue
2017
Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy
Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyPT3 prostate cancerRobot-assisted radical prostatectomyPathologic Gleason scoreBiochemical recurrenceRadical prostatectomyClinical progressionProstate cancerLymphovascular invasionRisk stratificationRisk factorsDisease progressionMultivariate Cox proportional regression analysisCox proportional regression analysisAdverse pathologic featuresProportional regression analysisRisk stratification toolMore risk factorsStage pT3bFree survivalOncologic outcomesPathologic featuresStratification toolGleason scoreOptimal patient
2015
Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score
Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDisease-Free SurvivalHumansKallikreinsKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiation OncologyRadiotherapy, AdjuvantRetrospective StudiesSocieties, MedicalUnited StatesUrologyConceptsPositive surgical marginsGleason score 6Adjuvant radiotherapyGleason score 8BCR-free survivalRadical prostatectomyBiochemical recurrenceAmerican Urological AssociationPathologic stageGleason scoreScore 6BCR rateSurgical marginsScore 8Urological AssociationPathologic Gleason score 8Multivariate Cox regression analysisPathologic Gleason scoreSurgical margin statusCox regression analysisRadiation Oncology guidelinesAmerican SocietyASTRO guidelineIndependent predictorsMargin statusNeutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer
Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerAbsolute lymphocyte countAbsolute neutrophil countLow-risk prostate cancer patientsProstate cancer patientsProstate cancerLymphocyte countANC groupLymphocyte ratioBiochemical recurrenceCancer patientsActive surveillanceHigher prostate-specific antigen levelMetastatic castration-resistant prostate cancerLow-risk PCa patientsProstate-specific antigen levelHigh absolute lymphocyte countCastration-resistant prostate cancerBiochemical recurrence-free survivalRobot-assisted radical prostatectomyAdverse pathologic outcomesAppropriate patient selectionKaplan-Meier methodRecurrence-free survivalRisk stratification tool
2014
DHCR24 is an Independent Predictor of Progression in Patients with Non-Muscle-Invasive Urothelial Carcinoma, and Its Functional Role is Involved in the Aggressive Properties of Urothelial Carcinoma Cells
Lee G, Ha Y, Jung Y, Moon S, Kang H, Lee O, Joung J, Choi Y, Yun S, Kim W, Kim I. DHCR24 is an Independent Predictor of Progression in Patients with Non-Muscle-Invasive Urothelial Carcinoma, and Its Functional Role is Involved in the Aggressive Properties of Urothelial Carcinoma Cells. Annals Of Surgical Oncology 2014, 21: 538-545. PMID: 24562935, DOI: 10.1245/s10434-014-3560-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAndrostenesCarcinomaCell AdhesionCell Line, TumorCell MovementCell ProliferationCell SurvivalDisease ProgressionDisease-Free SurvivalFemaleGene ExpressionGene Knockdown TechniquesHumansMaleMiddle AgedNeoplasm InvasivenessNerve Tissue ProteinsOxidoreductases Acting on CH-CH Group DonorsRNA, MessengerUrinary Bladder NeoplasmsYoung AdultConceptsUrothelial carcinoma cellsMRNA expression levelsIndependent predictorsUrothelial carcinomaImmunohistochemical stainingNon-muscle invasive urothelial carcinomaMultivariate Cox regression analysisCarcinoma cellsHuman UC cellsCox regression analysisKaplan-Meier estimatesInvasive urothelial carcinomaAggressive propertiesHuman urothelial carcinoma cellsExpression levelsProgression-related genesDHCR24 expressionExpression groupFunctional roleClinical relevanceGene signaturePatientsUC cellsProgressionHigh grade
2012
RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression
Jeong P, Min B, Ha Y, Song P, Kim I, Ryu K, Kim J, Yun S, Kim W. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression. European Journal Of Surgical Oncology 2012, 38: 1095-1100. PMID: 22884471, DOI: 10.1016/j.ejso.2012.07.116.Peer-Reviewed Original ResearchConceptsNon-muscle invasive bladder cancerNormal adjacent urotheliumInvasive bladder cancerTransurethral resectionNormal urotheliumAdjacent urotheliumRUNX3 methylationRUNX3 promoter methylationNMIBC patientsBladder cancerTumor tissueMultivariate Cox regression analysisUrothelium of patientsCox regression analysisKaplan-Meier estimatesPromoter methylationBladder tumor developmentNormal adjacent tissuesMethylation-specific polymerase chain reactionIndependent predictorsTumor numberPolymerase chain reactionPatientsSignificant associationTumor progression
2007
Expression of Bone Morphogenetic Proteins, the Subfamily of the Transforming Growth Factor-β Superfamily, in Renal Cell Carcinoma
Kwak C, Park Y, Kim I, Moon K, Ku J. Expression of Bone Morphogenetic Proteins, the Subfamily of the Transforming Growth Factor-β Superfamily, in Renal Cell Carcinoma. Journal Of Urology 2007, 178: 1062-1067. PMID: 17644140, DOI: 10.1016/j.juro.2007.05.005.Peer-Reviewed Original ResearchConceptsBone morphogenetic proteinBone morphogenetic protein 4Morphogenetic proteinsBone morphogenetic protein-7 expressionGrowth factor β superfamilyProtein-7 expressionTransforming Growth Factor-β SuperfamilyBone morphogenetic protein-4 expressionBone morphogenetic protein expressionProtein 4Largest subfamilyProtein expression rateCell typesProtein 4 expressionProteinProtein expressionSubfamiliesRenal cell carcinomaExpressionExpression rateSuperfamilyClear cell typePotential expressionCell carcinomaProtein immunoreactivity